炎症性肠病患者接种两剂SARS-CoV-2 mRNA疫苗后3个月抗体应答
该研究评估217例完成标准两剂SARS-CoV-2 mRNA疫苗接种的炎症性肠病患者,在接种后至少3个月时抗受体结合域抗体应答。结果显示98.6%的患者抗体阳性,部分使用抗肿瘤坏死因子-α的患者在3个月时抗体滴度下降;约10%在1个月时高滴度者3个月时降至低阳性滴度,多见于联合治疗和抗肿瘤坏死因子-α单药治疗者。作者认为需更大规模纵向研究明确应答及临床影响。
要点
- 98.6%的炎症性肠病患者在接种两剂SARS-CoV-2 mRNA疫苗后至少3个月时抗受体结合域抗体阳性。
- 部分使用抗肿瘤坏死因子-α的患者在3个月时抗体滴度下降。
- 约10%在1个月时高滴度者3个月时降至低阳性滴度,多见于联合治疗和抗肿瘤坏死因子-α单药治疗者。
核心结论
- 几乎所有(98.6%)炎症性肠病疫苗接种者在接种后至少3个月时具有阳性抗受体结合域抗体应答。
- 部分使用抗肿瘤坏死因子-α的患者在3个月时抗体滴度下降。
- 约10%在1个月时高滴度者3个月时降至低阳性滴度,多见于联合治疗和抗肿瘤坏死因子-α单药治疗者。
- 需要更大规模的纵向研究来明确炎症性肠病人群的应答及其临床影响。
研究设计与样本
- 研究纳入217例完成标准两剂SARS-CoV-2 mRNA疫苗系列的炎症性肠病患者,观察3个月内的抗受体结合域抗体应答。
主要发现
- 98.6%的炎症性肠病疫苗接种者在接种后至少3个月时抗受体结合域抗体阳性。
- 部分使用抗肿瘤坏死因子-α的患者在3个月时抗体滴度下降。
- 约10%在1个月时高滴度者3个月时降至低阳性滴度,多见于联合治疗和抗肿瘤坏死因子-α单药治疗者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更大规模的纵向研究来明确炎症性肠病人群的应答及其临床影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations. METHODS: We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series. RESULTS: Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy. DISCUSSION: Larger longitudinal studies are required to define the response in IBD population and its clinical impact.
引用
- Tsipotis E, Frey S, Connolly C, et al. Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2022. PMID: 35103023. doi:10.14309/ajg.0000000000001668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。